Product Description
For Metabolic Syndrome. A traditional Chinese Formula extract from Astragalus, Radix Puerariae and Cortex Mori is mixed into instant noodles. Patients are treated with AMP-1915 as meal. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02605655)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Shanghai Sundise Traditional Chinese Medicine
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Metabolic Syndrome X
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02605655 |
ShanghaiUTCM-01 | P1 |
Completed |
Metabolic Syndrome X |
2014-12-01 |
2019-03-20 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|